Speed of Processing Training for Cognitive Impairment

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cognitive Impairment+1 MoreSpeed of Processing Training - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new therapy to improve thinking skills and how well patients can carry out tasks in their daily lives. The therapy involves intensive, repetitive cognitive exercises for up to 3.5 hours a day for 10 consecutive weekdays, with rest periods as needed. Patients will be randomly assigned to receive the therapy soon or about three months later.

Eligible Conditions
  • Cognitive Impairment
  • Coronavirus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
MIND foods
1
AKL-T01
2
Cariprazine

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Change from Day 0 to Day 17

Day 17
Assessment of Motor and Process Skills (AMPS)
Canadian Occupation Performance Measure (COPM)
Cognitive Task Activity Log (CTAL) How Well Scale
Cognitive Task Activity Log (CTAL) Independence Scale
Improved and New Cognitive Ability (INCA)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
MIND foods
2
AKL-T01
3
Cariprazine

Trial Design

1 Treatment Group

Immediate Treatment
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Speed of Processing Training · No Placebo Group · N/A

Immediate TreatmentExperimental Group · 3 Interventions: Speed of Processing Training, Instrumental Activities of Daily Living Shaping, Transfer Package from CI Therapy · Intervention Types: Behavioral, Behavioral, Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Speed of Processing Training
2011
N/A
~340

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: change from day 0 to day 17

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,435 Previous Clinical Trials
2,229,194 Total Patients Enrolled
Edward TaubPrincipal Investigator - University of Alabama at Birmingham
University of Alabama at Birmingham
1 Previous Clinical Trials
60 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
There is a presence of cognitive impairment due to the Covid-19 infection.
Someone who has mild-to-moderate general cognitive impairment has a score between 10-25 on the Montreal Cognitive Assessment.
is confirmed After confirmation of positive status for Covid-19, at least three months must elapse before the individual is considered for release from isolation.
The person is physically and mentally healthy enough to participate in the study.
without aid The person is able to do things such as follow directions, remember information, and complete the UFOV and CTAL without help.
You have adequate sight and hearing to complete UFOV test.
You must be 18 years or older to enter this site
You are a resident of the community.\n
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top